The Thomson Reuters Pharma Knowledge Hub is an essential online repository of industry facts, trends and analysis. In one place, we’ve gathered the information that can help you enhance your discovery and development activities, and arm your decision-making.
- Hot off the Press
Objectively identifying key opinion leaders (KOLs), scientific experts or clinical investigators to collaborate with can be an onerous task.Thomson Reuters discusses the regulatory aspects of the KOL / industry relationship, proposes a primary means of determining KOL relevance, discusses methods for identifying KOLs to suit your business strategy, and proposes a solution for optimal KOL identification and selection.
Download our white paper, Key Opinion Leader Identification and Selection, to receive your complimentary copy.
Thomson Reuters believes that biomarkers will become one of the major driving forces of pharmaceutical research and drug development in the coming years.- Receive the latest Biomarkers White Paper: Biomarkers: An indispensable addition to the drug development toolkit
- Biomarkers, Drug Development and the Advent of Personalized Medicine Presented by Dr Jeffery Ross, Albany Medical College, New York.
- Recent Trends
APRIL - JUNE 2008
- Promising drugs moving through the pipeline show pharmaceutical companies aren’t scared to address the big issues with new treatments for cancer and hepatitis C virus infection. The Ones to Watch
- Novartis makes the biggest impact on medical research. Who’s Making the Biggest Splash?
- See the trends in global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output over the last 10 years.
- Historical Trends by Category
Enhance your presentations and reports with clearly presented information on historical trends in the pharmaceutical industry
- Clinical: A deeper looks at look some key geographic and enrolment trends affecting clinical development timelines globally.
- Development Pipeline: Theanalysis represented in this area looks at trends from a number ofangles including mode of actions, therapy area, stage of development,and R&D expenditure.
- Generics:An examination of global generics opportunities and launch trends aswell as taking a look at effects on the growth and development of thegeneric industry such as patent challenges and the API supply.
- Marketing & Messages:Results displayed here look at key commercial trends such as revenuesby therapy area and company size as well as the impact messagespublished in journal articles, abstracts, monographs, posters…have onthe attitudes and treatment habits of prescribing clinicians.
- Patents:A slide representation of the analysis of key data sources related topatent activity such as the number of pharmaceutical patentapplications and granted patents from the five major patent issuingauthorities
- R&D Expenditure: The analysis represented in this area looks at trends from a number of angles.
- Regulatory:Analysis of some key geographic trends as well as some trends relatedto submission and market approval times and data on the number of NASand NME launches.
Download your free slides today!
What are our experts saying?
